Ligand Pharmaceuticals
LGND | NASDAQ
$290.93
+$0.86 (+0.30%)
Sep 22, 2026, 10:41 AM ET · Market open
Market Data
Market Cap $5.81B
Enterprise Value $5.23B
Beta 0.98
Average Volume 313.68K
Shares Outstanding (Diluted) 21.84M
Shares Change YoY 9.59%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US53220K5048
Price Performance
Price Change 1M 1.3%
Price Change 3M 3.8%
Price Change 6M 41.8%
Price Change YTD 52.6%
Price Change 1Y 69.9%
Price Change 3Y 391.0%
Price Change 5Y 234.1%
1M CAGR (ann.) -1.1%
1Y CAGR (ann.) 70.8%
5Y CAGR (ann.) 28.4%
All-Time CAGR 12.0%
Valuation
PE Ratio 31.02
Forward PE 23.35
PEG Ratio 0.03
Forward PEG 0.96
PS Ratio 20.01
Forward PS 15.10
PB Ratio 6.01
P/FCF Ratio 44.25
P/Adj. FCF Ratio 74.43
P/OCF Ratio 44.22
EV/Sales 18.00
EV/EBIT 21.82
EV/EBITDA 19.11
EV/FCF 39.82
Earnings Yield 3.2%
FCF Yield 2.3%
Adj. FCF Yield 1.3%
Financial Health
Net Cash $582.22M
Total Debt $1.13B
Cash & Short-Term Investments $1.36B
Total Assets $2.19B
Current Ratio 31.18
Quick Ratio 30.96
Debt / Equity Ratio 1.17
Debt / EBITDA 4.12
Debt / FCF 8.58
OCF / Debt 0.12
Interest Coverage 16.31
Altman Z-Score 4.51
Piotroski F-Score 5
Margins & Profitability
Gross Profit Margin 98.6%
Operating Profit Margin 34.7%
EBITDA Margin 94.2%
Net Profit Margin 67.9%
FCF Margin 45.2%
Adj. FCF Margin 26.9%
SBC / Revenue 18.3%
SBC Impact (per share) -40.6%
Returns
Return on Assets 9.0%
Return on Equity 20.1%
Return on Invested Capital 3.9%
Return on Capital Employed 4.7%
Return on Tangible Assets 10.5%
Historical Growth (CAGR)
Revenue CAGR 3Y 22.9%
Revenue CAGR 5Y 2.9%
Revenue CAGR 10Y 12.7%
EPS CAGR 3Y 86.6%
EPS CAGR 5Y 27.6%
EPS CAGR 10Y -0.3%
FCF CAGR 3Y 10.3%
FCF CAGR 5Y 34.6%
FCF CAGR 10Y 20.6%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 18
EPS Growth Next 3Y 17.8%
Revenue Growth Next 3Y 23.8%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) $2.28
EPS Growth Est (next Q) -26.2%
Revenue Est (next Q) $78.09M
Revenue Growth Est (next Q) -32.4%
Fair Value Estimates
Graham Number $100.72
Graham Upside -65.3%
Lynch Fair Value $233.75
Lynch Upside -19.4%
Price Target $338.50
Price Target Upside 16.7%
Cash Flow
Operating Cash Flow $131.64M
Free Cash Flow $131.37M
Adj. Free Cash Flow $78.1M
FCF Per Share $6.55
OCF Per Share $6.56
OCF/S Ratio 45.3%
Income Statement
Revenue $290.54M
Gross Profit $289.64M
Operating Income $100.93M
EBITDA $273.74M
Net Income $197.22M
EPS (Diluted) $9.35
Revenue / Employee $6.18M
Profit / Employee $4.2M
Employees 47
Add to Watchlist
Select watchlists to add or remove LGND